

**United States
Securities and Exchange Commission
Washington, D.C. 20549**

**SCHEDULE 13D
(Rule 13d-101)**

**Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a)
Under the Securities Exchange Act of 1934
(Amendment No. 9)***

Medpace Holdings, Inc.

(Name of Issuer)

Common Stock
(Title of Class of Securities)

58506Q109
(CUSIP Number)

August J. Troendle
c/o Medpace Holdings, Inc.
5375 Medpace Way
Cincinnati, OH 45227
Tel: (513) 579-9911

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 28, 2020
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES OF REPORTING PERSONS August J. Troendle	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	SOURCE OF FUNDS PF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION United States	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 616,643
	8	SHARED VOTING POWER 7,327,558
	9	SOLE DISPOSITIVE POWER 616,643
	10	SHARED DISPOSITIVE POWER 7,327,558
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,680,437	
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 24.0%	
14	TYPE OF REPORTING PERSON IN	

1	NAMES OF REPORTING PERSONS Medpace Investors, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	SOURCE OF FUNDS OO	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 7,327,558
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 7,327,558
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,517,348	
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 20.8%	
14	TYPE OF REPORTING PERSON OO (Limited liability company)	

This Amendment No. 9 to the Schedule 13D (this “Amendment No. 9”) amends and supplements the Statement on Schedule 13D filed with the United States Securities and Exchange Commission on August 26, 2016, as amended by Amendment No. 1 filed on August 8, 2018, Amendment No. 2 filed on October 2, 2018, Amendment No. 3 filed on February 6, 2019, Amendment No. 4 filed on August 5, 2019, Amendment No. 5 filed on August 7, 2019, Amendment No. 6 filed on August 15, 2019, Amendment No. 7 filed on September 17, 2019 and Amendment No. 8 filed on May 8, 2020 (collectively, the “Statement”), relating to the common stock (the “Common Stock”), of Medpace Holdings, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meaning set forth in the Statement.

Item 4. Purpose of Transaction

Item 4 of the Statement is amended and supplemented by inserting the following information:

The responses to Items 5 and 6 of this Schedule 13D are incorporated herein by reference.

On March 4, 2020, Medpace Investors, LLC (“MPI”) entered into a written stock selling plan in accordance with Rule 10b5-1 (the “2020 MPI Plan”).

Item 5. Interest in Securities of the Issuer

Item 5 of the Statement is amended and restated in its entirety as follows:

(a) - (b): See Items 7 – 13 of the cover pages above.

(c): MPI sold 463,208 shares in open market transactions under the 2020 MPI Plan, as follows:

Trade Date	Shares Sold	Price Per Share
7/9/2020	2,455	\$ 100.15(1)
7/13/2020	5,503	\$ 100.43(2)
7/13/2020	624	\$ 101.13(3)
7/15/2020	573	\$ 101.74(4)
7/15/2020	3,634	\$ 103.37(5)
7/15/2020	4,876	\$ 104.27(6)
7/15/2020	15,230	\$ 105.26(7)
7/15/2020	4,387	\$ 106.01(8)
7/16/2020	14,356	\$ 103.64(9)
7/16/2020	917	\$ 104.61(10)
7/17/2020	2,774	\$ 103.90(11)
7/17/2020	7,501	\$ 105.23(12)
7/17/2020	9,034	\$ 105.82(13)
7/20/2020	7,647	\$ 105.05(14)
7/20/2020	10,088	\$ 105.78(15)
7/21/2020	5,999	\$ 106.03(16)
7/21/2020	20,016	\$ 106.93(17)

7/21/2020	2,075	\$ 107.48(18)
7/22/2020	641	\$ 107.17(19)
7/22/2020	3,001	\$ 108.93(20)
7/22/2020	12,796	\$ 109.62(21)
7/22/2020	17,680	\$ 110.42(22)
7/22/2020	1,760	\$ 111.14(23)
7/23/2020	11,297	\$ 110.42(24)
7/23/2020	5,302	\$ 111.37(25)
7/23/2020	4,913	\$ 112.35(26)
7/23/2020	9,606	\$ 113.34(27)
7/23/2020	625	\$ 114.00(28)
7/24/2020	27,158	\$ 105.93(29)
7/24/2020	6,245	\$ 106.58(30)
7/24/2020	684	\$ 108.10(31)
7/24/2020	293	\$ 110.04
7/27/2020	746	\$ 106.95(32)
7/27/2020	1,352	\$ 108.22(33)
7/27/2020	7,458	\$ 109.46(34)
7/27/2020	9,234	\$ 110.17(35)
7/27/2020	4,762	\$ 111.43(36)
7/27/2020	5,467	\$ 112.33(37)
7/28/2020	8,387	\$ 117.20(38)
7/28/2020	11,642	\$ 118.24(39)
7/28/2020	16,306	\$ 119.24(40)
7/28/2020	14,186	\$ 120.23(41)
7/28/2020	24,883	\$ 121.17(42)
7/28/2020	19,844	\$ 122.26(43)
7/28/2020	6,917	\$ 123.09(44)
7/28/2020	8,629	\$ 124.50(45)
7/28/2020	15,160	\$ 125.07(46)
7/28/2020	2,007	\$ 126.17(47)
7/28/2020	3,183	\$ 127.75(48)
7/28/2020	5,614	\$ 128.70(49)
7/28/2020	3,500	\$ 129.54(50)
7/28/2020	2,968	\$ 130.89(51)
7/28/2020	667	\$ 131.84(52)
7/28/2020	2,770	\$ 132.92(53)
7/28/2020	4,530	\$ 133.98(54)
7/28/2020	9,142	\$ 134.90(55)
7/28/2020	6,030	\$ 135.91(56)
7/28/2020	17,417	\$ 137.14(57)
7/28/2020	13,806	\$ 137.98(58)
7/28/2020	5,500	\$ 138.90(59)
7/28/2020	2,011	\$ 139.94(60)

7/28/2020	2,346	\$ 141.39(61)
7/28/2020	3,764	\$ 142.21(62)
7/28/2020	3,038	\$ 143.24(63)
7/28/2020	252	\$ 143.96(64)

(1) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$100.00 to \$100.56. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(2) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$100.00 to \$100.995. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(3) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$101.03 to \$101.215. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(4) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$101.48 to \$101.965. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(5) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$102.805 to \$103.805. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(6) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$103.81 to \$104.81. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(7) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$104.815 to \$105.815. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(8) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$105.82 to \$106.305. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(9) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$103.16 to \$104.15. The Reporting Person undertakes to

provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(10) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$104.215 to \$105.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(11) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$103.43 to \$104.30. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(12) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$104.565 to \$105.565. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(13) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$105.57 to \$106.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(14) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$104.385 to \$105.385. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(15) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$105.39 to \$106.345. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(16) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$105.32 to \$106.31. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(17) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$106.33 to \$107.33. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(18) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$107.34 to \$107.74. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(19) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$106.89 to \$107.78. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(20) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$108.05 to \$109.05. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(21) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$109.055 to \$110.05. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(22) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$110.06 to \$111.06. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(23) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$111.065 to \$111.26. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(24) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$109.82 to \$110.815. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(25) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$110.845 to \$111.84. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(26) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$111.86 to \$112.85. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(27) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$112.915 to \$113.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(28) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$113.95 to \$114.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(29) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$105.41 to \$106.41. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(30) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$106.415 to \$107.26. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(31) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$107.51 to \$108.835. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(32) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$106.69 to \$107.655. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(33) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$107.72 to \$108.60. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(34) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$108.82 to \$109.82. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(35) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$109.835 to \$110.81. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(36) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$110.87 to \$111.825. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(37) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$111.945 to \$112.55. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(38) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$116.765 to \$117.60. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(39) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$117.67 to \$118.67. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(40) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$118.675 to \$119.675. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(41) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$119.70 to \$120.695. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(42) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$120.705 to \$121.675. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(43) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$121.72 to \$122.71. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(44) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$122.725 to \$123.69. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(45) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$123.735 to \$124.73. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(46) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$124.74 to \$125.69. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(47) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$125.745 to \$126.715. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(48) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$127.22 to \$128.215. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(49) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$128.23 to \$129.23. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(50) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$129.26 to \$130.215. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(51) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$130.31 to \$131.265. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(52) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$131.385 to \$132.28. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(53) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$132.41 to \$133.32. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(54) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$133.425 to \$134.415. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(55) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$134.45 to \$135.45. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(56) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$135.515 to \$136.515. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(57) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$136.52 to \$137.505. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(58) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$137.525 to \$138.515. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(59) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$138.53 to \$139.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(60) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$139.54 to \$140.52. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(61) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$140.755 to \$141.75. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(62) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$141.76 to \$142.685. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(63) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$142.885 to \$143.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(64) The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$143.94 to \$143.965. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

(d): None.

(e): Not Applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of the Statement is amended and supplemented as follows:

Item 4 above summarizes certain provisions of the 2020 MPI Plan and is incorporated herein by reference. A copy of the 2020 MPI Plan is attached as Exhibit 7 hereto, and is incorporated by reference.

Except as set forth herein and the Statement, none of the Reporting Persons or Related Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including, but not limited to, any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

Item 7. Materials to be Filed as Exhibits

<u>Exhibit Number</u>	<u>Description</u>
1	Joint Filing Agreement*
2	Voting Agreement*
3	Registration Rights Agreement*
4	Form of Lock-Up Agreement*
5	Rule 10b5-1 Stock Trading Plan of Medpace Investors, LLC dated August 20, 2018*
6	Rule 10b5-1 Stock Trading Plan of Medpace Investors, LLC dated November 15, 2018*
7	Rule 10b5-1 Stock Trading Plan of Medpace Investors, LLC dated March 4, 2020

* Filed in the Statement.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 30, 2020

/s/ August J. Troendle
August J. Troendle

Medpace Investors, LLC

/s/ August J. Troendle
Name: August J. Troendle
Title: Sole Manager



Rule 10b5-1 Trading Plan

This Trading Plan (the "Trading Plan") is entered into on 03/04/2020 ("Seller's Adoption Date")

(MM/DD/YYYY)

between **Medpace Investors LLC** ("Seller") and UBS Financial Services Inc. ("UBSFS") for the purpose of selling, in accordance with Rule 10b5-1(c) (1) of the Securities Exchange Act of 1934 as amended (the "Exchange Act"), shares of common stock of **Medpace Holdings, Inc.** ("Issuer"), **MEDP** (Ticker) listed on Exhibit A ("Stock"), which may include shares that the Seller has the right to acquire under outstanding stock options ("the Options"); shares that are acquired by Seller pursuant to the Issuer's employee stock purchase plan (the "ESPP Stock"); shares that are acquired upon vesting of outstanding restricted stock units/awards from Issuer ("RSUs/RSAs"); and shares that are acquired upon vesting of outstanding performance share awards from Issuer ("PSAs").

Seller and UBSFS agree as follows:

1. Specific Plan of Sale. UBSFS, acting as agent, agrees to effect sales of Stock on behalf of Seller in accordance with the specific instructions set forth in Exhibit A (the "Trading Instructions") and the other provisions of this Trading Plan as set forth below. UBSFS's obligations under this Trading Plan will not take effect until UBSFS (by countersigning) approves and accepts this Trading Plan.
2. Fees/Commissions. [REDACTED]
3. Seller's Representations and Warranties. Seller represents and warrants that:
 - (a) Seller is not aware of any material nonpublic information concerning Issuer or any securities of Issuer;
 - (b) Seller is entering into this Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1;
 - (c) Seller has informed Issuer of this Trading Plan, has furnished Issuer with a copy of this Trading Plan, and has determined that this Trading Plan is consistent with Issuer's insider trading policy;
 - (d) Seller has disclosed to UBSFS any agreements that Seller is currently party to, or within the past 60 days has been party to, with another broker, dealer or financial institution (each, a "Financial Institution") entered into for the purpose of establishing a trading plan that complies with Rule 10b5-1;
 - (e) Seller is not subject to any legal, regulatory or contractual restriction or undertaking that would be violated or breached by UBSFS conducting sales in accordance with this Trading Plan;
 - (f) the Stock to be sold under this Trading Plan is owned free and clear by Seller and is not subject to any liens, security interests or other encumbrances or limitations on dispositions, other than those imposed by Rule 144 or Rule 145 under the Securities Act of 1933, as amended (the "Securities Act"), if applicable; and
 - (g) Seller has had an opportunity to consult with Seller's own advisors as to the legal, tax, financial and other aspects of this Trading Plan, including this Trading Plan's compliance with Rule 10b5-1 and applicable state law. Seller has not received or relied on any representations from UBSFS concerning this Trading Plan's compliance with Rule 10b5-1.
4. Agreements by Seller. Seller acknowledges and agrees to the following provisions:
 - (a) Brokerage Account. Seller shall open a sole-purpose UBSFS brokerage account in the name of and for the benefit of Seller (the "Plan Account"), prior to acceptance and approval of this Trading Plan by the 10b5-1 Group of UBSFS.
 - (b) Delivery of Stock. Seller shall deliver all shares of Stock, including restricted securities, as defined in Rule 144, to be sold pursuant to this Trading Plan into the Plan Account prior to the commencement of any sales under this Trading Plan. This excludes any Options, PSAs, RSAs, RSUs, or ESPP shares to be sold under the Trading Plan as listed in Exhibit A. If the amount of Stock to be sold is designated as an aggregate dollar amount, Seller agrees to deliver shares of Stock in an amount to be agreed upon by Seller and UBSFS as sufficient to effect sales anticipated under this Trading Plan, and upon notification from UBSFS that the number of shares of Stock in the Plan Account is less than the number of shares that UBSFS estimates are to be sold pursuant to this Trading Plan, Seller agrees to deliver promptly to the Plan Account the number of shares of Stock specified by UBSFS as necessary to eliminate this shortfall.

- (c) Hedging Transactions. While this Trading Plan is in effect, Seller shall comply with the prohibition set forth in Rule 10b5-1(c)(1)(i)(C) against entering into or altering a corresponding or hedging transaction or position with respect to the Issuer's stock.
 - (d) Notice to UBSFS. Seller shall notify UBSFS to terminate or suspend sales, as appropriate, as soon as practicable upon the occurrence of any of the events contemplated in paragraph 7(a) or (b) or paragraph 8(c).
 - (e) Communications. Seller shall not, directly or indirectly, communicate any material nonpublic information relating to the Stock or Issuer to any employee of the UBSFS 10b5-1 Group or any UBSFS Financial Advisor.
 - (f) Compliance with Applicable Laws and Required Exchange Act Filings. Seller shall comply with all laws, rules and regulations applicable or related to this Trading Plan and the sale of Stock hereunder, and Seller shall make all filings required under Sections 13 and 16 of the Exchange Act in connection with this Trading Plan in a timely manner.
 - (g) No Influence. After his/her execution of this Trading Plan, Seller shall not attempt to exercise, any influence over how, when or whether to effect sales of Stock pursuant to this Trading Plan.
 - (h) Stock Non-Marginable. The Stock is not marginable and may not be used by Seller as collateral for any purpose.
 - (i) Execution, Average Pricing and Pro Rata Allocation of Sales. UBSFS may sell Stock on any national securities exchange, in the over-the-counter market, on an automated trading system or otherwise. UBSFS or one of its affiliates may make a market in the Stock and may act as principal in executing sales under the Trading Plan. To the extent that UBSFS administers other trading plans relating to Issuer's securities, UBSFS may aggregate orders for Seller with orders under other sellers' trading plans for execution in a block and allocate each execution on a pro rata basis to each seller. In the event of partial execution of block orders, UBSFS shall allocate the proceeds of all Stock actually sold on a particular day pursuant to all Rule 10b5-1 trading plans concerning Issuer's securities that UBSFS manages pro rata based on the ratio of (x) the number of shares to be sold pursuant to the order instructions of each Trading Plan to (y) the total number of shares to be sold under all Trading Plans having the same type of order instructions.
 - (j) Exclusivity. Until this Trading Plan has been terminated, Seller shall not enter into any agreement with, give any instructions to, or adopt a plan for trading with another Financial Institution with respect to the purchase or sale of the Stock or the Options that are referenced in Exhibit A of the plan, for the purpose of establishing a trading plan that complies with Rule 10b5-1.
 - (k) Acknowledgment of Relief from Obligation to Effect Sales. UBSFS shall be relieved of its obligation to sell Stock as otherwise required by paragraph 1 above at any time when:
 - (i) UBSFS has determined in good faith that (A) it is prohibited from doing so by a legal, contractual or regulatory restriction applicable to it or its affiliates or to Seller or Seller's affiliates; or (B) selling Stock is impracticable as the result of a material adverse change in the financial markets or in the market activity of the Stock, or as the result of an 'act of God' as described in paragraph 10(b)(i) below or (C) a trading suspension with respect to the Stock by the Securities and Exchange Commission or the primary listed exchange or a delisting of the Stock or a banking moratorium has occurred; if UBSFS cannot effect a sale for any of such reasons, UBSFS shall effect such sale as promptly as practical after the cessation or termination of such cause, subject to the restrictions set forth in paragraph 1 of Exhibit A;
 - (ii) This Trading Plan is suspended in accordance with paragraph 7 below; or
 - (iii) This Trading Plan is terminated in accordance with paragraph 8 below.
5. Rule 144 and Rule 145. With respect to sales of Stock subject to Rule 144 or Rule 145 under the Securities Act, Seller and UBSFS agree to comply with the following provisions:
- (a) Agreements by Seller Regarding Rule 144 and Rule 145.
 - (i) Seller agrees not to take, and agrees to cause any person or entity with which Seller would be required to aggregate sales of Stock pursuant to Rule 144(a)(2) or (e) not to take, any action that would cause the sales hereunder not to meet all applicable requirements of Rule 144 or Rule 145.

- (ii) Seller agrees to complete, execute and deliver to UBSFS, Forms 144 for sales to be effected under the Trading Plan at such times and in such numbers as UBSFS shall reasonably request. Seller hereby grants UBSFS a power of attorney to complete and file on behalf of Seller any Forms 144 as required by applicable law, rule or regulation in order to sell Stock pursuant to this Trading Plan in accordance with Rule 144.
 - (iii) Seller agrees to complete, execute and deliver to UBSFS Rule 144 Seller's Representation Letters (in the form attached as Exhibit C) for sales to be effected under the Trading Plan at such times and in such numbers as UBSFS shall request.
 - (iv) Seller agrees to notify the 10b5-1 Group of UBSFS immediately if there is any change in Seller's employment, affiliate or non-affiliate status.
- (b) Agreements by UBSFS Regarding Rule 144 and Rule 145.
- (i) UBSFS agrees to conduct all sales pursuant to the Trading Plan in accordance with the manner of sale requirement of Rule 144. UBSFS shall not affect any sales that it knows would exceed the then-applicable volume limitation under Rule 144.
 - (ii) UBSFS agrees to file such Forms 144 furnished by Seller pursuant to paragraph 5(a)(ii) on behalf of Seller as required by applicable law.
 - (iii) UBSFS agrees to submit such Rule 144 Seller's Representation Letters furnished by Seller pursuant to paragraph 5(a)(iii) on behalf of Seller as required by Issuer's transfer agent.
6. Options. If applicable, Seller and UBSFS agree to the provisions regarding the exercise of Options contained in Exhibit A.
- (a) Seller's Representations and Warranties.
- (i) Seller represents and warrants that the Options listed in Exhibit A are held free and clear without liens, security interests or other encumbrances or limitations on exercise of the vested portion thereof, other than the requirement that Seller comply with the exercise provisions of such Options; and
 - (ii) The shares of Stock acquired through exercise of the Options shall be held free and clear by Seller without liens, security interests or other encumbrances or limitations on disposition.
- (b) Delivery.
- (i) Seller agrees to complete, execute and deliver to UBSFS Stock Option Exercise Notices in the form provided by Issuer, for the exercise of Options pursuant to the Trading Plan at such times and in such numbers as UBSFS shall reasonably request. Seller hereby authorizes UBSFS to deliver such Stock Option Exercise Notices to Issuer on Seller's behalf as necessary to effectuate such exercises and settle the sales of Stock underlying such Options under the Trading Plan. Seller agrees to make appropriate arrangements to ensure that Stock received upon the exercise of Options shall be delivered to the Plan Account promptly after Issuer's receipt of the applicable Stock Option Exercise Form.
 - (ii) UBSFS shall be relieved of its obligation to exercise Options and sell Stock as otherwise required at any time when Seller has failed to deliver Stock Options Exercise Notices or underlying Stock.
- (c) Exercise.
- (i) Pursuant to an appropriately and fully completed Stock Option Exercise Notice received from Seller, UBSFS shall exercise Options necessary to effect sales of underlying Stock in the manner specified in Exhibit A.
 - (ii) UBSFS shall, in connection with the exercise of Options, remit to Issuer the exercise price along with such amounts as may be necessary to satisfy withholding obligations. These amounts shall be deducted from the proceeds of sale of the Stock, together with late fees, if applicable.
 - (iii) UBSFS shall in no event exercise any Option if, at the time of exercise, the cost of the Option exercise (plus fees and commissions) is equal to or greater than the market value of the Stock.

7. Suspension. Sales under this Trading Plan shall be suspended as follows:
- (a) Promptly after the date on which UBSFS receives notice from Seller or Issuer of legal, contractual or regulatory restrictions applicable to Seller or Seller's affiliates that would be violated by UBSFS selling Stock under this Trading Plan (such notice merely stating that there is a restriction applicable to Seller without specifying the reasons for the restriction), including a restriction based on Seller's awareness of material nonpublic information in connection with a tender offer for Issuer's securities (transactions on the basis of which Rule 14e-3 of the Exchange Act could be violated). The Seller or the Issuer will notify UBSFS in writing of its intention and specify the beginning date and the ending date, to the extent that it's known, of the suspension or temporary withdrawal period. The notice shall be provided no less than two (2) business days prior to the beginning or the end of suspension date. For the avoidance of doubt, this paragraph is meant to allow, but not obligate, Issuer to provide a suspension notice in accordance with this paragraph.
 - (b) In the event of a Qualifying Securities Offering, promptly after the date on which UBSFS receives notice from Issuer or Seller of the Suspension Date until UBSFS receives notice from Issuer or Seller of the Resumption Date; *provided, however*, that (i) Seller certifies that Seller has no control over the Suspension Date or the Resumption Date, and (ii) if Seller is unable to make such certification then this paragraph shall result in a termination of the Trading Plan, rather than suspension.

"Qualifying Securities Offering" means any offering of securities of Issuer for cash in which the lead underwriter, lead manager, initial purchaser, placement agent or other entity performing a similar function (each, an "Underwriter") requires Seller to agree to restrict Seller's ability to effect sales pursuant to this Trading Plan.

"Suspension Date" means the date on which a preliminary prospectus, offering memorandum, offering circular or other disclosure document (each, a "Preliminary Offering Document") is first used to market securities of Issuer by the Underwriter, or if a Preliminary Offering Document is not used, the date on which the underwriting agreement, purchase agreement, placement agent agreement or similar agreement (each, an "Underwriting Agreement") is entered into by the Underwriter and Issuer.

"Resumption Date" means the day immediately following the expiration of the time period during which Seller was restricted from effecting sales pursuant to this Trading Plan in accordance with the Underwriting Agreement.

For the avoidance of doubt, this paragraph is meant to allow, but not obligate, Issuer to provide a suspension notice in accordance with this paragraph.
 - (c) In the event that the 10b5-1 Group of UBSFS becomes aware of material nonpublic information concerning Issuer or the Stock, UBSFS may be required by applicable law or, in its sole discretion, find it advisable, to suspend sales under this Trading Plan. In such case, UBSFS shall promptly notify Seller of the suspension of sales under this Trading Plan.
8. Termination. This Trading Plan will terminate on the earliest to occur of the following:
- (a) at the close of trading on [REDACTED];
 - (b) promptly after the date on which UBSFS receives notice from Seller of the termination of this Trading Plan, in which case, Seller agrees to notify the Issuer promptly of such termination;
 - (c) upon the reasonable determination by UBSFS, or promptly after the reasonable determination by Seller and notice to UBSFS, that this Trading Plan does not comply with Rule 10b5-1;
 - (d) promptly after the date UBSFS is notified of the death of Seller;
 - (e) immediately in the event that Seller fails to deliver any Stock pursuant to paragraph 4(b) or fails to satisfy the delivery requirements with respect to Stock underlying Options set forth herein; or
 - (f) the date that the aggregate number of shares of Stock sold pursuant to this Trading Plan reaches 1,000,000 shares.
9. Confidentiality. UBSFS will maintain the confidentiality of this Plan and will not, without the advance written permission of Seller, disclose the specific terms of this Trading Plan to any person or entity, except: (i) to those persons who reasonably need to know the information in the execution and administration of the Trading Plan (including the Issuer); (ii) to respond to any inquiry from the Securities and Exchange Commission, FINRA, NYSE, NASDAQ, or any other self-regulatory organization, any State securities regulator, or any other governmental or quasi-governmental authority regarding the Trading Plan; or (iii) to any other person or entity to the extent such disclosure is required by law or regulation, or by a subpoena issued by a court of competent jurisdiction.

10. Indemnification: Limitation of Liability.

(a) Indemnification.

- (i) Seller agrees to indemnify and hold harmless UBSFS and its directors, officers, employees and affiliates from and against all claims, losses, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) (collectively, "Losses") arising out of or attributable to (A) UBSFS's compliance (by act or omission) with this Trading Plan, other than as set forth in Section 10(a)(ii) below, (B) any breach by Seller of this Trading Plan (including Seller's representations and warranties hereunder), or (C) any violation by Seller of applicable laws or regulations related to or in connection with this Trading Plan, except, in each instance, to the extent caused by UBSFS's breach of this Trading Plan, gross negligence or willful misconduct. This indemnification shall survive termination of this Trading Plan.
- (ii) UBSFS agrees to indemnify and hold harmless Seller from and against all Losses arising out of or attributable to UBSFS's breach of this Trading Plan or its gross negligence or willful misconduct in connection with this Trading Plan.

(b) Limitation of Liability.

- (i) Notwithstanding any other provision hereof, UBSFS shall not be liable to Seller, and Seller shall not be liable to UBSFS, for: (A) special, indirect, punitive, exemplary or consequential damages, or incidental losses or damages of any kind, even if advised of the possibility of such losses or damages or if such losses or damages could have been reasonably foreseen; or (B) any failure to perform or to cease performance or any delay in performance that results from a cause or circumstance that is beyond its reasonable control, including, but not limited to, failure of electronic or mechanical equipment, strikes, failure of common carrier or utility systems, severe weather, market disruptions or other causes commonly known as "acts of God".
- (ii) Notwithstanding any other provision hereof, UBSFS shall not be liable to Seller for (A) the exercise of discretionary authority or discretionary control pursuant to this Trading Plan, if any, or (B) any failure to effect a sale required by paragraph 1, except for failures to effect sales as a result of the gross negligence or willful misconduct of UBSFS

11. Agreement to Arbitrate. Any dispute between Seller and UBSFS arising out of, relating to or in connection with this Trading Plan or any transaction relating to this Trading Plan shall be determined only by arbitration as provided in the UBSFS brokerage account agreement referred to in paragraph 4(a).

12. Notices.

- (a) All notices to UBSFS under this Trading Plan shall be provided in writing to the **10b5-1 Group of UBSFS** by facsimile at fax number **201-352-4728**.
- (b) All notices to Seller under this Trading Plan shall be provided by mail to the address below:

**5375 Medpace Way
Cincinnati, OH 45227**

- (c) UBSFS will provide notification of all sales of Stock and exercise of Options under this Trading Plan to Seller and to Issuer by e-mail at the below addresses by 6 p.m. (ET) on the date of execution on a best efforts basis, with a final report by 12 p.m. (ET) on the following business day. Seller and Issuer agree to notify UBSFS in writing of any changes to the contact information provided.

**a.troendle@medpace.com
s.ewald@medpace.com
michael.sexton@ubs.com
chris.morency@ubs.com**

13. Amendments and Modifications. This Trading Plan and the Exhibits hereto may be amended by Seller only upon the written consent of UBSFS and receipt by UBSFS of the following documents, each dated as of the date of such amendment:
 - (a) a certificate signed by Seller, certifying that the representations and warranties of Seller contained in this Trading Plan are true at and as of the date of such certificate as if made at and as of such date; and
 - (b) an issuer certificate completed by Issuer substantially in the form of Exhibit B.
14. Inconsistency with Law. If any provision of this Trading Plan is or becomes inconsistent with any applicable present or future law, rule or regulation, that provision will be deemed modified or, if necessary, rescinded in order to comply with the relevant law, rule or regulation. All other provisions of this Trading Plan will continue and remain in full force and effect.
15. Governing Law. This Trading Plan shall be governed by and construed in accordance with the internal laws of the State of New York.
16. Entire Agreement. This Trading Plan, including Exhibits, and the brokerage account agreement referred to in paragraph 4(a) above, constitute the entire agreement between the parties with respect to this Trading Plan and supersede any prior agreements or understandings with regard to this Trading Plan.
17. Counterparts. This Trading Plan may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument; *provided, however* that (i) Seller's Adoption Date is the same date that Seller signed this Trading Plan and its Exhibits, (ii) the Trading Plan Effective Date may be no sooner than 2 weeks following the Seller's Adoption Date, (iii) the Issuer's Certification Date, as defined in Exhibit B, may not be earlier than the Seller's Adoption Date, and (iv) UBSFS will not approve and accept this Trading Plan on any date that is prior to the Seller's Adoption Date or the Issuer's Certification Date.

SELLER REPRESENTS AND WARRANTS THAT THEY WILL RETAIN A COPY OF THIS TRADING PLAN AFTER EXECUTING/DATING IT BELOW.

NOTICE: THIS AGREEMENT CONTAINS A PREDISPUTE ARBITRATION CLAUSE IN PARAGRAPH 11.

IN WITNESS WHEREOF, the undersigned have signed this Trading Plan as of the date specified below.

MEDPACE INVESTORS LLC

/s/ Dr. August J. Troendle _____ 4-MAR-2020
 Name: **Dr. August J. Troendle** Date
 Title:

NOTICE: Signature date above must be the same as Seller's Adoption Date as defined in the opening section of this Trading Plan.

ACCEPTED BY: UBS FINANCIAL SERVICES INC.

 Name: Denis Murphy Date
 Title: Director

 Name: Christopher DeLuca Date
 Title: Executive Director

EXHIBIT B
ISSUER CERTIFICATE

1. **Medpace Holdings Inc.** (“Issuer”) acknowledges that it has received, reviewed and retained a copy of the Trading Plan dated 4 MAR 2020 the (“Trading Plan”) between **Medpace Investors LLC** (“Seller”) and UBSFS relating to the common stock of Issuer (the “Stock”); provided, however, that Issuer makes no representation or warranty concerning the Trading Plan or whether it complies with Rule 10b5-1 or any other applicable laws or regulations.
2. Issuer believes that the Trading Plan is consistent with its insider trading policies, and has no reason to believe that there are any legal, contractual or regulatory restrictions applicable to Seller or Seller’s affiliates as of the date of hereof that would prohibit Seller from either entering into the Trading Plan or selling Stock pursuant to the Trading Plan.
3. To avoid delays in connection with transfers of stock certificates and settlement of transactions involving restricted securities, if any, under the Trading Plan, and in acknowledgment of UBS Financial Services Inc.’s agreement in the Trading Plan that sales of Stock under the Trading Plan will be effected in compliance with Rule 144, Issuer agrees that it will, within a commercially reasonable time after Issuer’s receipt of evidence, reasonably satisfactory to Issuer and its counsel, that Rule 144 has been complied with, instruct its transfer agent to process the transfer of shares and issue a new certificate to Seller’s transferee or nominee that does not bear any legend or statement restricting its transferability to a buyer.
4. If client is exercising options under the Trading Plan then the Issuer acknowledges that Seller has authorized UBSFS to serve as Seller’s agent and attorney-in-fact to exercise certain Options to purchase the Stock from time to time pursuant to the Trading Plan. Issuer agrees to accept, acknowledge and effect the exercise of such Options by UBSFS and the delivery of the underlying Stock to UBSFS (free of any legend or statement restricting its transferability to a buyer) upon receipt of a completed Stock Option Exercise Form (if required).

IN WITNESS WHEREOF, the undersigned have signed this Issuer Certificate as of the date specified below (“Issuer’s Certification Date”)

<u>/s/ Stephen P. Ewald</u>	<u>4-MAR-2020</u>
Name: Stephen P. Ewald	Date
Title: General Counsel	

NOTICE: Signature date may not be earlier than Seller’s Adoption Date as defined in the opening section of this Trading Plan.

EXHIBIT C

This Exhibit C may not be amended except in accordance with the Trading Plan

RULE 144 LETTER

UBS Financial Services Inc.
Attn: 10b5-1 Group
1000 Harbor Blvd, 7th Floor
Weehawken, NJ 07086

Medpace Holdings Inc.
5375 Medpace Way
Cincinnati, OH 45227

Ladies and Gentlemen:

In conjunction with my order(s) to sell shares of common stock of **Medpace Holdings Inc.** ("Issuer") ("the Stock"), through you as broker or dealer for my account pursuant to the Rule 10b5-1 Trading Plan dated 4 MAR 2020 (the "Trading Plan"), under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), I advise you as follows:

1. I intend to sell Stock pursuant to Rule 10b5-1. I intend for UBS Financial Services Inc. to adhere to the Trading Plan without alteration or modification during the plan period.
2. I am an affiliate of the Issuer.
3. The number of shares of Stock, which I have ordered you to sell as broker or dealer for my account, will conform to the Sales Instructions in Exhibit A of the Trading Plan.
4. I have verified that Issuer has been subject to the Securities and Exchange Commission (the "SEC") information reporting requirements pursuant to the Exchange Act for at least the preceding 90 days and has filed all required periodic reports during the 12 months preceding the first sale or during any shorter period that the SEC may require. As of the date of the Trading Plan, I did not know of any material nonpublic information concerning Issuer.
5. If the securities being sold are "restricted securities" as defined in paragraph (a)(3) of Rule 144, I confirm that I have been the beneficial owner for a period of at least six (6) months as provided in paragraph (d) of Rule 144.
6.
 - a) I have not solicited or arranged for the solicitation of any orders to buy in anticipation or in connection with my proposed sales.
 - b) I have made no payments to any other person in connection with your execution of my order.
 - c) I have not agreed to act in concert with any other person in connection with my proposed sales.
7. It is my bona fide intention to sell the Stock as expressly prescribed in the Trading Plan pursuant to the Plan.
8. I understand that the payment of the proceeds of the sales will be delayed until the shares of Stock are transferred and delivered free of restrictions to UBS Financial Services Inc.
9. All capitalized terms used in this Rule 144 Letter shall have the meanings ascribed to them in the Trading Plan.

The undersigned agrees to notify UBS Financial Services Inc. immediately if any of the above representations become inaccurate before the sales are completed.

Very truly yours,

/s/ August J. Troendle
Signature of the Seller

August J. Troendle, on behalf of
Medpace Investors LLC
Print Name

5375 Medpace Way
Cincinnati, OH 45227
Seller's Address

4-MAR-2020
Date